|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Oxidized low-density lipoprotein activates adipophilin through ERK1/2 signal pathway in RAW264.7 cells显示文摘它被报导了那氧化低密度的脂蛋白(Ox-LDL ) 能增加 adipophilin 的表示。然而,详细机制充分没被理解。这研究的目的是在 adipophilin 表示和细胞内部的类脂化合物微滴累积上调查 Ox-LDL 的机制。一个鼠标像巨噬细胞的房间线, RAW264.7,全部被使用,并且 Ox-LDL 以一种剂量依赖者方式导致了 adipophilin 表示,这被发现。而且, Ox-LDL 导致了 peroxisome 激活 proliferator 的受体 --(PPAR ) 表示和 PPAR 特定的禁止者 T0070907 没废除 Ox-LDL-induced adipophilin 表示,而是特定的收缩筋 GW1929。而且, Ox-LDL 导致了 ERK1/2 的 phosphorylation,并且由 PD98059 的 ERK1/2-specific 抑制压制了 Ox-LDL-induced PPAR 和 adipophilin 表示。结果显示出那 ERK1/2 或 PPAR 特定的抑制减少了细胞内部的类脂化合物微滴的数量。同时, PPAR 特定的收缩筋增加了细胞内部的类脂化合物微滴。这些结果建议 Ox-LDL-induced 经由 ERK1/2 激活在 adipophilin 水平增加是在 RAW264.7 房间导致细胞内部的类脂化合物微滴的更大的数量的机制之一,它显示 adipophilin 涉及动脉粥样硬化患者前进。 | Qingnan Liu Zhibing Dai Zhiqiang Liu Xiaohui Liu Chaoke Tang Zuo Wang Guanghui Yi Lushan Liu Zhisheng Jiang Yongzong Yang Zhonghua Yuan | 2010 | Acta Biochimica et Biophysica Sinica2010，42，9： | 13 |
| 2 | Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study显示文摘Background:Famitinib is a tyrosine kinase inhibitor against multiple targets,including vascular endothelial growth factor receptor 2/3,platelet-derived growth factor receptor,and stem cell factor receptor(c-kit).Previous studies have demonstrated anti-tumour activities of famitinib against a wide variety of advanced-stage solid cancers.We aimed to determine the safety and efficacy of famitinib with concurrent chemoradiotherapy(CCRT)in patients with locoregionally advanced nasopharyngeal carcinoma(NPC).We also evaluated the feasibility of contrast-enhanced ultrasound(D-CEUS)as a predictor of early tumour response to famitinib and to correlate functional parameters with clinical efficacy.Methods:The trial was conducted in subjects with stage III or IVa-b NPC using a 3+3 design of escalating fami-tinib doses.Briefly,subjects received 2 weeks of famitinib monotherapy followed by 7 weeks of famitinib plus CCRT.D-CEUS of the neck lymph nodes was performed at day 0,8 and 15 after famitinib was administered before starting concurrent chemoradiotherapy.End points included safety,tolerability and anti-tumour activity.Results:Twenty patients were enrolled(six each for 12.5,16.5 and 20 mg and two for 25 mg).Two patients in the 25 mg cohort developed dose-limiting toxicities,including grade 4 thrombocytopenia and grade 3 hypertension.The most common grade 3/4 adverse events were leukopenia,neutropenia and radiation mucositis.D-CEUS tests showed that more than 60%of patients achieved a perfusion parameter response after 2 weeks taking famitinib alone,and the parameter response was associated with disease improvement.In the famitinib monotherapy stage,three patients(15%)showed partial responses.The complete response rate was 65%at the completion of treatment and 95%3 months after the treatment ended.After a median follow-up of 44 months,the 3-year progression-free survival(PFS)and distant metastasis-free survival were 70%and 75%,respectively.Subjects with a decrease of perfusion parameter response,such as peak intensity decreased at least 30%after 1 week of famitinib treatment,had higher 3-year PFS(90.9%vs.44.4%,95%CI 73.7%-100%vs.11.9%-76.9%,P<0.001)than those with an increase or a reduction of less than 30%.Conclusions:The recommended famitinib dose for phase II trial is 20 mg with CCRT for patients with local advanced NPC.D-CEUS is a reliable and early measure of efficacy for famitinib therapies.Further investigation is required to confirm the effects of famitinib plus chemoradiotherapy. | Qiuyan Chen Linquan Tang Na Liu Feng Han Ling Guo Shanshan Guo Jianwei Wang Huai Liu Yanfang Ye Lu Zhang Liting Liu Pan Wang Yingqin Li Qingmei He Xiaoqun Yang Qingnan Tang Yang Li YuJing Liang XueSong Sun Chuanmiao Xie Yunxian Mo Ying Guo Rui Sun Haoyuan Mo Kajia Cao Xiang Guo Musheng Zeng Haiqiang Mai Jun Ma | 2018 | Cancer Communications2018，38，1： | 6 |
| 3 | Establishment of a prognostic scoring model for regional recurrent nasopharyngeal carcinoma after neck dissection显示文摘Objective:The main aim of this study was to establish a scoring model to predict risk of progression and survival in patients with regionally recurrent nasopharyngeal carcinoma(NPC).Methods:Three hundred and forty-eight patients subjected to neck dissection from 2003 to 2017 were included for study.Clinicopathologic information for each patient was analyzed.Independent prognostic factors were selected using the Cox proportional hazards model and incorporated into the scoring model.Concordance index(C-index)and calibration curves were used to verify discrimination and calibration,respectively and the results validated using bootstrap resampling.Results:Microscopic positive lymph node>2[hazard ratio(HR),2.19;95%confidence interval(CI),1.30–3.68;P=0.003],extranodal extension(HR,2.75;95%CI,1.69–4.47;P<0.001),and lower neck involvement(HR,1.78;95%CI,1.04–3.04;P=0.034)were identified from multivariate analysis as independent factors for overall survival(OS).A qualitative 4-point scale was generated to stratify patients into 4 risk groups for predicting OS and progression-free survival(PFS).The novel scoring model demonstrated enhanced discrimination(C-index=0.69;95%CI,0.62–0.76)relative to the original recurrent tumor-node-metastasis(rTNM)staging system(C-index=0.56;95%CI,0.50–0.62),and was internally validated with a bootstrap-adjusted C-index of 0.70.The calibration curve showed good agreement between predicted probabilities and actual observations.Conclusions:The scoring system established in this study based on a large regionally recurrent NPC cohort fills a gap regarding assessment of risk and prediction of survival outcomes after neck dissection in this population and could be further applied to identify high-risk patients who may benefit from more aggressive intervention. | Xiaoyun Li Chao Lin Jinjie Yan Qiuyan Chen Xuesong Sun Sailan Liu Shanshan Guo Liting Liu Haojun Xie Qingnan Tang Yujing Liang Ling Guo Hao Li Xuekui Liu Xiang Guo Linquan Tang Haiqiang Mai | 2020 | Cancer Biology & Medicine2020，17，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员